Nanobiotix (NasdaqGS:NBTX) FY Conference November 10, 2025 04:30 PM ET Speaker1I'm good.Speaker035 questions.Speaker1I have tough questions for you. All right, so welcome to this fireside chat with Nanobiotix. We've saved the best for last today. With us today, we have Laurent Lévy, CEO. Welcome, Laurent. Thanks for joining us. Maybe, again, stepping back, just could you give us a quick overview of your technology? I know you have three different platforms that you have developed. Maybe describe those to us ...

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killingLyell management will host an investor webcast at 8:30 AM ET today SOUTH SAN FRANCISCO, Calif., Nov. 10, 20 ...